Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06120374
Recruiting
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Not applicable · China · 3 sites
Registry update: 30 Dec 2025
NCT06892860
Recruiting
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Phase 2 · Spain, France, United Kingdom · 3 sites
Registry update: 6 May 2026
2024-520006-19-00
Recruiting
Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasive bladder cancer versus the standard immunotherapy.
Phase 4 · Spain · 20 sites
Registry update: 9 Oct 2025
NCT05176483
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Phase 1 · Austria, Australia, Belgium, Switzerland, Germany, Spain, France, United Kingdom, Israel, Italy, New Zealand, Poland, United States · 114 sites
Registry update: 1 Oct 2026
NCT05072600
Recruiting
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Phase 2 · China · 1 site
Registry update: 10 Jan 2022
NCT05102110
Recruiting
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
Not applicable · United Kingdom · 1 site
Registry update: 16 Mar 2026
NCT04865939
Recruiting
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
Phase 3 · United States · 1 site
Registry update: 17 Aug 2026
NCT04970472
Recruiting
Bio Clinical Collection of Urothelial Carcinoma
Not applicable · France · 1 site
Registry update: 19 Mar 2026
NCT04628767
Recruiting
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Phase 2/3 · United States · 258 sites
Registry update: 9 Nov 2026
NCT05126472
Recruiting
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1/2 · United States · 7 sites
Registry update: 14 Aug 2026
NCT05107674
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · United Kingdom, United States · 17 sites
Registry update: 9 Sept 2025
NCT05059444
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not applicable · Germany, Spain, France, Italy, United States · 57 sites
Registry update: 14 Sept 2026
NCT05204186
Recruiting
Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence
Not applicable · France · 1 site
Registry update: 15 Jun 2026
NCT04977453
Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/2 · South Korea, United States · 12 sites
Registry update: 19 Oct 2026
NCT04878029
Recruiting
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · United States · 1 site
Registry update: 29 Apr 2026
NCT05231655
Recruiting
Ex VIvo DEtermiNed Cancer Therapy
Not applicable · United Kingdom · 1 site
Registry update: 24 Feb 2025
NCT05123625
Recruiting
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
Not applicable · China · 1 site
Registry update: 5 Aug 2025
NCT04498767
Recruiting
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Not applicable · Belgium, Switzerland, Germany, France, United Kingdom, Italy, Poland · 13 sites
Registry update: 26 Aug 2024
NCT04861584
Recruiting
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
Phase 2 · China · 1 site
Registry update: 9 Oct 2026
NCT04678362
Recruiting
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma
Phase 2 · France · 15 sites
Registry update: 22 Sept 2025

Ordered by registry start date. Freshness and sponsorship never change the order.